Literature DB >> 34306369

A correlation analysis of the serum hepcidin concentrations and viral loads in HCV-infected patients.

Rongqi Wang1, Suxian Zhao1, Jinghua Du1, Jie Qiao1, Wencong Li1, Yuemin Nan1.   

Abstract

OBJECTIVE: To investigate the correlation between the serum hepcidin levels and the viral loads in hepatitis C virus (HCV) infected patients.
METHODS: Sixty HCV-infected patients (the study group) and 50 healthy controls (the control group) were recruited as the study cohort. The liver function and inflammation-related parameters were compared, and the 60 HCV patients were divided into mild (G1-G2), moderate (G3), and severe (G4) groups according to each patient's inflammatory activity grade (G). The serum iron (SI), ferritin (SF), and transferrin (TRF), hepcidin levels were compared. The relationships between the HCV-RNA, HCV Ag, HCV Ab, albumin (ALB), total bilirubin (TBIL), aminotransferase (ALT), and aspartate aminotransferase (AST) levels and the hepcidin levels was analyzed. The SI, SF, IL-6, ALT, AST, and TBIL levels were significantly higher, and the hepcidin, TRF, and ALB levels were significantly lower in the study group than they were in the control group (P<0.05). The G4 patients' SI and SF levels were significantly higher than they were in the G3 and the G1-G2 groups (P<0.05). The TRF and hepcidin levels in the G1-G2 group were significantly higher than they were in the G3 and G4 groups (P<0.05). The HCV-RNA, HCV Ag, and HCV Ab levels were negatively correlated with the hepcidin levels (r=-0.7679, r=-0.9062, r=-0.6095, P<0.05), positively correlated with the serum ALB, TBIL, and ALT levels (r=0.9792, r=0.9759, r=0.8236, P<0.05), and not significantly correlated with the AST levels (r=-0.2803, P>0.05).
CONCLUSION: The HCV patients' serum hepcidin levels showed an abnormal decrease, suggesting that HCV patients may have an iron metabolism disorder, which indicates that there is a possibility of evaluating the HCV patients' conditions by measuring the hepcidin levels and of improving HCV patients' prognoses by regulating the iron metabolism. AJTR
Copyright © 2021.

Entities:  

Keywords:  HCV; Hepatitis C; correlation analysis; hepcidin; viral load

Year:  2021        PMID: 34306369      PMCID: PMC8290691     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

1.  Validation of inflammation-based prognostic models in patients with hepatitis B-associated hepatocellular carcinoma: a retrospective observational study.

Authors:  Qing Pang; Lei Zhou; Kai Qu; Rui-Xia Cui; Hao Jin; Hui-Chun Liu
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 2.566

2.  Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues.

Authors:  Enagnon K Alidjinou; Charlotte Michel; Valérie Canva; Faïza Ajana; Didier Hober; Laurence Bocket
Journal:  J Med Virol       Date:  2018-01-30       Impact factor: 2.327

3.  Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.

Authors:  Ashraf O Abdelaziz; Hend I Shousha; Ebada M Said; Zeinab A Soliman; Ahmed A Shehata; Mohamed M Nabil; Ahmed H Abdelmaksoud; Tamer M Elbaz; Fatma M Abdelsalam
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-11       Impact factor: 2.566

4.  Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Authors:  Xavier Adhoute; Guillaume Penaranda; Jean Luc Raoul; Floriane Sellier; Paul Castellani; Valerie Oules; Herve Perrier; Gaëlle Lefolgoc; Bernard Pol; Manuela Campanile; Olivier Bayle; Patrick Beaurain; Olivier Monnet; Marc Bourlière
Journal:  Eur J Gastroenterol Hepatol       Date:  2018-04       Impact factor: 2.566

5.  Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area.

Authors:  H Y Kim; J Y Nam; J-H Lee; H A Lee; Y Chang; H Y Lee; H Cho; D H Lee; Y Y Cho; E J Cho; S J Yu; J M Lee; Y J Kim; J-H Yoon
Journal:  Aliment Pharmacol Ther       Date:  2018-04-02       Impact factor: 8.171

6.  Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.

Authors:  Berthold Bivigou-Mboumba; Marie Amougou-Atsama; Samira Zoa-Assoumou; Hervé M'boyis Kamdem; Guy Francis Nzengui-Nzengui; Angélique Ndojyi-Mbiguino; Richard Njouom; Sandrine François-Souquière
Journal:  PLoS One       Date:  2018-01-09       Impact factor: 3.240

7.  Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents.

Authors:  Claudia Westermann; Dana Wendeler; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2018-05-25       Impact factor: 2.646

8.  Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway.

Authors:  Yisha Liang; Xuezhi Cao; Qiang Ding; Yanan Zhao; Zhenliang He; Jin Zhong
Journal:  PLoS Pathog       Date:  2018-05-21       Impact factor: 6.823

9.  Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015.

Authors:  Janneke P Bil; Peter Ag Schrooders; Maria Prins; Peter M Kouw; Judith He Klomp; Maarten Scholing; Lutje Phm Huijbregts; Gerard Jb Sonder; Toos Chfm Waegemaekers; Henry Jc de Vries; Wieneke Meijer; Freke R Zuure; Alma Tostmann
Journal:  Euro Surveill       Date:  2018-03

10.  Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.

Authors:  Kouichi Kitamura; Lusheng Que; Miyuki Shimadu; Miki Koura; Yuuki Ishihara; Kousho Wakae; Takashi Nakamura; Koichi Watashi; Takaji Wakita; Masamichi Muramatsu
Journal:  PLoS Pathog       Date:  2018-06-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.